IGC Pharma (DB:IGS1) - Hisse Senedi Fiyatı, Haberler ve Analizler

IGS1 Stoklara Genel Bakış

Klinik aşamada bir ilaç şirketi olan IGC Pharma, Inc. Alzheimer hastalığı için tedavi geliştirmektedir. Daha fazla detay

IGS1 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Gelirin yılda 10.15% oranında artması öngörülüyor

Risk Analizi

1 yıldan az nakit akışı var

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir geliri yok ( $1M )

Anlamlı bir piyasa değeri yok ( €28M )

+ 2 daha fazla risk

IGC Pharma, Inc. Rakipler

SynBiotic

DUSE:SBX

€27.9m

Biofrontera

XTRA:B8FK

€16.4m

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€57.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IGC Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.33
52 Haftanın En Yüksek Seviyesi	US$0.69
52 Haftanın En Düşük Seviyesi	US$0.23
Beta	1.29
11 Aylık Değişim	-3.51%
3 Aylık Değişim	4.43%
1 Yıllık Değişim	22.22%
33 Yıllık Değişim	-72.25%
5 Yıllık Değişim	-51.87%
Halka arzdan bu yana değişim	-96.92%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	IGS1	DE Pharmaceuticals	DE Pazar
7D	6.5%	1.4%	0.8%
1Y	22.2%	-18.4%	9.1%

Getiri vs. Endüstri: IGS1 geçen yıl % -18.4 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: IGS1 geçen yıl % 9.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is IGS1's price volatile compared to industry and market?
IGS1 volatility
IGS1 Average Weekly Movement	9.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: IGS1 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: IGS1 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2005	67	Ram Mukunda	igcpharma.com

Klinik aşamada bir ilaç şirketi olan IGC Pharma, Inc. Alzheimer hastalığı için tedaviler geliştirmektedir. Şirketin öncü ürünü, Alzheimer'a bağlı demansta ajitasyon tedavisi olarak Faz 2B klinik çalışmasında olan IGC-AD1 ve klinik öncesi geliştirme aşamasında olan TGR-63, IGC-1C, IGC-M3 ve LMP'dir. Şirket daha önce India Globalization Capital, Inc. olarak biliniyordu ve Mart 2023'te adını IGC Pharma, Inc. olarak değiştirdi.

IGC Pharma, Inc. Temel Bilgiler Özeti

IGC Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IGS1 temel i̇stati̇sti̇kler
Piyasa değeri	€26.27m
Kazançlar(TTM)	-€11.98m
Gelir(TTM)	€1.13m

24.6x

P/S Oranı

-2.3x

F/K Oranı

IGS1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IGS1 gelir tablosu (TTM)
Gelir	US$1.18m
Gelir Maliyeti	US$518.00k
Brüt Kâr	US$665.00k
Diğer Giderler	US$13.23m
Kazançlar	-US$12.57m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.16
Brüt Marj	56.21%
Net Kâr Marjı	-1,062.47%
Borç/Özkaynak Oranı	1.8%

IGS1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IGS1 Stoklara Genel Bakış

Ödüller

Risk Analizi

IGC Pharma, Inc. Rakipler

DUSE:SBX

€27.9m

XTRA:B8FK

€16.4m

DB:0RX

€65.0m

XTRA:HIGH

€57.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Second quarter 2025 earnings released: US$0.023 loss per share (vs US$0.045 loss in 2Q 2024)

IGC Pharma, Inc. Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Independent Director recently bought €179k worth of stock

IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Recent updates

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Second quarter 2025 earnings released: US$0.023 loss per share (vs US$0.045 loss in 2Q 2024)

IGC Pharma, Inc. Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Independent Director recently bought €179k worth of stock

IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma, Inc. Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

First quarter 2025 earnings released: US$0.033 loss per share (vs US$0.039 loss in 1Q 2024)

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

IGC Pharma's Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

Full year 2024 earnings released: US$0.22 loss per share (vs US$0.22 loss in FY 2023)

IGC Pharma, Inc.'S TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, A Key Hallmark of Alzheimer's Disease

IGC Pharma, Inc. Announces Patient Enrollment At Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer’S At Week Two Compared to Placebo

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $6.24051 million.

Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors

Third quarter 2024 earnings released: US$0.088 loss per share (vs US$0.042 loss in 3Q 2023)

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.309602 million.

Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer’S Trial

Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.047 loss in 2Q 2023)

IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico

IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited and other investors

IGC Pharma, Inc. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.042 loss per share (vs US$0.047 loss in 3Q 2022)

India Globalization Capital, Inc. Receives No Objection Letter from Health Canada

India Globalization Capital, Inc. Announces Board Changes

India Globalization Capital, Inc. Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

Second quarter 2023 earnings released: US$0.047 loss per share (vs US$0.087 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.054 loss per share (vs US$0.037 loss in 1Q 2022)

India Globalization Capital, Inc., Annual General Meeting, Sep 09, 2022

Full year 2022 earnings released: US$0.30 loss per share (vs US$0.21 loss in FY 2021)

India Globalization Capital, Inc. Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

India Globalization Capital, Inc. Announces Final Approval of Settlement of Shareholder Class Action Lawsuits

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

India Globalization Capital, Inc. Announces Positive Primary Endpoint Data for Its Phase 1 Clinical Trial for IGC-AD1

India Globalization Capital, Inc. Announces Preliminary Results for its Exploratory Endpoints from its Phase 1 IGC-AD1 Clinical Trial

India Globalization Capital, Inc. to Present Preliminary Positive Secondary End Point Findings from its Phase 1 Clinical Trial for IGC-AD1

Second quarter 2022 earnings released: US$0.087 loss per share (vs US$0.04 loss in 2Q 2021)

India Globalization Capital, Inc. Completes Its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

First quarter 2022 earnings released: US$0.037 loss per share (vs US$0.047 loss in 1Q 2021)

India Globalization Capital, Inc Announces Issuance of Patent for the Treatment of Alzheimer’S Disease Using THC

India Globalization Capital, Inc. Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. Completes Cohort 1 of Its Phase 1 Thc-Based Clinical Trial on Alzheimer’S Patients

Independent Chairman of the Board recently sold €75k worth of stock

India Globalization Capital, Inc. Provides Update on Phase 1 Clinical Trial on Alzheimer’S Patients

Third quarter 2021 earnings released: US$0.056 loss per share (vs US$0.041 loss in 3Q 2020)

New 90-day high: €2.09

India Globalization Capital, Inc. Approves the Election of John E. Lynch to the Board of Directors

India Globalization Capital, Inc., Annual General Meeting, Jan 11, 2021

India Globalization Capital, Inc. Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’S Patients

India Globalization Capital, Inc. announced delayed 10-Q filing

India Globalization Capital, Inc. announced delayed 10-Q filing